Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.

We have seen 56 institutional investors add shares of $STRO stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports.

March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

The STRO Companies is a content partner of Bisnow and have worked with our Studio B team to develop creative content and custom offerings. The STRO Companies actively pursue new “value-add” an ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sutro Biopharma (STRO – Research Report) and ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...